Cementos Bio-B (CEMENTOS) - Net Assets
Based on the latest financial reports, Cementos Bio-B (CEMENTOS) has net assets worth CL$288.81 Billion CLP (≈ $322.99 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CL$528.13 Billion ≈ $590.64 Million USD) and total liabilities (CL$239.33 Billion ≈ $267.65 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cementos Bio-B asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CL$288.81 Billion |
| % of Total Assets | 54.68% |
| Annual Growth Rate | 1.31% |
| 5-Year Change | 12.28% |
| 10-Year Change | 38.31% |
| Growth Volatility | 7.39 |
Cementos Bio-B - Net Assets Trend (2014–2025)
This chart illustrates how Cementos Bio-B's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Cementos Bio-B for the complete picture of this company's asset base.
Annual Net Assets for Cementos Bio-B (2014–2025)
The table below shows the annual net assets of Cementos Bio-B from 2014 to 2025. For live valuation and market cap data, see CEMENTOS market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CL$288.81 Billion ≈ $322.99 Million |
+6.68% |
| 2024-12-31 | CL$270.72 Billion ≈ $302.76 Million |
+5.62% |
| 2023-12-31 | CL$256.31 Billion ≈ $286.65 Million |
+6.07% |
| 2022-12-31 | CL$241.65 Billion ≈ $270.25 Million |
-6.05% |
| 2021-12-31 | CL$257.22 Billion ≈ $287.67 Million |
+5.59% |
| 2020-12-31 | CL$243.61 Billion ≈ $272.44 Million |
+2.42% |
| 2019-12-31 | CL$237.85 Billion ≈ $266.00 Million |
+2.59% |
| 2018-12-31 | CL$231.83 Billion ≈ $259.27 Million |
+5.09% |
| 2017-12-31 | CL$220.61 Billion ≈ $246.72 Million |
+5.65% |
| 2016-12-31 | CL$208.81 Billion ≈ $233.52 Million |
+3.21% |
| 2015-12-31 | CL$202.32 Billion ≈ $226.26 Million |
-19.17% |
| 2014-12-31 | CL$250.30 Billion ≈ $279.92 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cementos Bio-B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 120.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CL$164.51 Billion | 57.09% |
| Other Components | CL$123.64 Billion | 42.91% |
| Total Equity | CL$288.15 Billion | 100.00% |
Cementos Bio-B Competitors by Market Cap
The table below lists competitors of Cementos Bio-B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kearny Financial Corp
NASDAQ:KRNY
|
$511.24 Million |
|
Tactile Systems Technology Inc
NASDAQ:TCMD
|
$511.26 Million |
|
Shandong Lipeng Co Ltd
SHE:002374
|
$511.34 Million |
|
Nam Long Investment Corp
VN:NLG
|
$511.45 Million |
|
TSRC Corp
TW:2103
|
$511.18 Million |
|
Medigen Vaccine Biologics
TWO:6547
|
$511.14 Million |
|
Shanghai Ailu Package Co. Ltd.
SHE:301062
|
$511.11 Million |
|
Shanghai Weihong Electronic Technology Co Ltd
SHE:300508
|
$511.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cementos Bio-B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 270,071,331,000 to 288,150,098,000, a change of 18,078,767,000 (6.7%).
- Net income of 33,087,780,000 contributed positively to equity growth.
- Dividend payments of 138,697,000 reduced retained earnings.
- Other factors decreased equity by 14,870,316,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CL$33.09 Billion | +11.48% |
| Dividends Paid | CL$138.70 Million | -0.05% |
| Other Changes | CL$-14.87 Billion | -5.16% |
| Total Change | CL$- | 6.69% |
Book Value vs Market Value Analysis
This analysis compares Cementos Bio-B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.08x to 1.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CL$830.48 | CL$1730.00 | x |
| 2018-12-31 | CL$874.06 | CL$1730.00 | x |
| 2019-12-31 | CL$897.83 | CL$1730.00 | x |
| 2020-12-31 | CL$920.04 | CL$1730.00 | x |
| 2021-12-31 | CL$971.01 | CL$1730.00 | x |
| 2022-12-31 | CL$912.07 | CL$1730.00 | x |
| 2023-12-31 | CL$967.51 | CL$1730.00 | x |
| 2024-12-31 | CL$1022.14 | CL$1730.00 | x |
| 2025-12-31 | CL$1090.56 | CL$1730.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cementos Bio-B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.48%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.93%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 1.83x
- Recent ROE (11.48%) is above the historical average (8.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 8.76% | 7.16% | 0.56x | 2.20x | CL$-2.87 Billion |
| 2015 | 10.52% | 7.14% | 0.62x | 2.39x | CL$1.05 Billion |
| 2016 | 8.63% | 6.17% | 0.61x | 2.31x | CL$-2.85 Billion |
| 2017 | 10.87% | 8.95% | 0.61x | 2.00x | CL$1.92 Billion |
| 2018 | 8.56% | 7.53% | 0.58x | 1.95x | CL$-3.32 Billion |
| 2019 | 5.52% | 4.98% | 0.60x | 1.85x | CL$-10.62 Billion |
| 2020 | 5.66% | 5.70% | 0.54x | 1.84x | CL$-10.55 Billion |
| 2021 | 10.48% | 9.29% | 0.59x | 1.91x | CL$1.22 Billion |
| 2022 | 4.38% | 3.16% | 0.70x | 1.97x | CL$-13.54 Billion |
| 2023 | 8.92% | 6.53% | 0.71x | 1.92x | CL$-2.77 Billion |
| 2024 | 12.01% | 9.02% | 0.69x | 1.93x | CL$5.42 Billion |
| 2025 | 11.48% | 8.93% | 0.70x | 1.83x | CL$4.27 Billion |
Industry Comparison
This section compares Cementos Bio-B's net assets metrics with peer companies in the Building Materials industry.
Industry Context
- Industry: Building Materials
- Average net assets among peers: $227,603,017,500
- Average return on equity (ROE) among peers: 9.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cementos Bio-B (CEMENTOS) | CL$288.81 Billion | 8.76% | 0.83x | $511.20 Million |
| Melon SA (MELON) | $205.80 Billion | 5.97% | 0.94x | $212.52 Million |
| Compañía Industrial El Volcán S.A (VOLCAN) | $249.41 Billion | 13.34% | 0.50x | $260.65 Million |
About Cementos Bio-B
Cementos Bio Bio S.A. engages in the production and sale of cement, lime, and concrete products in Chile and internationally. The company operates through Cement and Lime segments. It offers ready-mixed concrete, gypsum, and limestone products. The company is also involved in the manufacture and sale of lime for use in the extraction of silver, gold, lithium, and iodine applications, as well as c… Read more